Market capitalization | $1.13b |
Enterprise Value | $1.03b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.10 |
P/S ratio (TTM) P/S ratio | 3.39 |
P/B ratio (TTM) P/B ratio | 6.51 |
Revenue growth (TTM) Revenue growth | 168.06% |
Revenue (TTM) Revenue | $333.62m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
12 Analysts have issued a Ardelyx, Inc. forecast:
12 Analysts have issued a Ardelyx, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 334 334 |
168%
168%
|
|
Gross Profit | 281 281 |
171%
171%
|
|
EBITDA | -26 -26 |
56%
56%
|
EBIT (Operating Income) EBIT | -28 -28 |
56%
56%
|
Net Profit | -39 -39 |
41%
41%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
Head office | United States |
CEO | Mike Raab |
Employees | 395 |
Founded | 2007 |
Website | www.ardelyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.